Origin & Journey
3S Pharma Consulting was founded in 2026 with a clear mission: to help pharmaceutical generics manufacturers confidently meet regulatory expectations while driving operational excellence. We partner with organizations to strengthen product development, remediation programs, quality systems, and regulatory compliance, enabling sustainable, inspection ready operations.
Backed by decades of global pharmaceutical experience, our team has worked extensively across Canadian, U.S., Middle Eastern, and international regulatory jurisdictions. We understand the pressure, complexity, and pace of today’s pharmaceutical environment and deliver pragmatic, tailored solutions aligned with your business goals.
Facility Technical Services
- Project planning and feasibility assessments
- Conceptual and basic engineering design
- Civil and structural engineering design
- Architectural and interior design for GMP
- Structural condition assessments and remediation
In addition, we implement digital infrastructures that support data integrity, regulatory compliance, and operational transparency, utilizing quality, engineering, and manufacturing data to enable AI supported insights.
40+
Combined Expertise
Our Mission
To empower pharmaceutical manufacturers with science-driven consulting that ensures patient safety, regulatory compliance, and unmatched operational speed through digital transformation and technical rigor.
Our Vision
To be the global benchmark in pharmaceutical engineering, where innovation meets integrity, creating a future where every pharmaceutical facility operates at peak efficiency and quality.
Rakesh Singh Chaudhary
Founder & Principal Advisor
Executive Leadership &
Scientific Rigor.
Rakesh Singh Chaudhary is founder and principal advisor of 3S Pharma Consulting. He is an executive leader in pharmaceutical industry with over four decades of scientific and leadership hands on experience across the global pharmaceutical generics industry. After graduating with Masters in Pharmaceutical Chemistry and Masters in International Business, he worked with Jayant Vitamins Limited, MJ Pharmaceuticals, Lupin Laboratories in India, Tabuk Pharmaceuticals Manufacturing Company (Saudi Arabia), GenPharm and Apotex Inc in Canada.
"Shaped by a disciplined upbringing as an Army brat, Rakesh brings integrity, accountability, and decisiveness to every problem he tackles."
Rakesh combines rigorous scientific knowledge with deep regulatory insight and strategic vision, enabling to move confidently through complex compliance and operational challenges. He established a research and development department for Tabuk Pharmaceutical Manufacturing Company in a record 16 months time and worked on the harmonization of process and systems across Canada, India and Mexico sites of Apotex.
A dedicated family man, Rakesh is also proud of his daughters, one a practicing physician in Internal Medicine in Hawaii, USA, and the other a validation associate in the Canadian generic pharmaceutical industry, further deepening his insight into both clinical and manufacturing perspectives of healthcare.
Rakesh is a prolific author, having published numerous scientific papers in internationally respected journals. He is deeply passionate about bridging science and real world applications, translating complex research into clear, practical insights.
Scientific Publications
A comprehensive body of peer-reviewed research across the pharmaceutical lifecycle, bridging science and real-world applications.
1. Determination of Diltiazem Hydrochloride in tablet formulation by non aqueous titrimetric method (1990).
2. Progress of Biotechnology in Pharmaceuticals (1992).
3. Determination of self generated alcohol from herbal oral liquid formulation (1992).
4. Dissolution system for nifedipine sustained release formulations (1993).
5. Reverse Phase High Performance Liquid Chromatography of Ketorolac (1993).
6. Determination of Diltiazem Hydrochloride in human serum by HPLC (1993).
7. A comparative pharmacokinetic evaluation of two marketed Ciprofloxacin (1993).
8. A comparative bioavailability two marketed Ofloxacin (1994).
9. HPTLC method for monitoring degradation products of rifampin (1994).
10. Dissolution test method for Rifampicin - Isoniazid (1994).
11. Bioequivalence of Atenolol tablets in healthy human volunteers (1994).
12. Stability testing of pharmaceuticals for worldwide marketing (1994).
13. Enteric Film coating, Jindal K. C., Chaudhary R. S., Khanna S., (1994).
14. Effect of buffers and pH on Rifampicin stability (1995).
15. Simultaneous determination of Metronidazole Benzoate (1999).
16. Application of a hot-melt granulation process (2016).
17. Continuous Manufacturing: A Generic Industry Perspective (2017).
18. Effect of Kollidon VA®64 particle size and morphology (2018).
19. Effect of substitution of plasticizer dibutyl phthalate (2019).
20. Evaluation of physically modified starch (1988).
21. Evaluation of DR profile of Ibuprofen tablets (1988).
22. Effect of hardness on DR profile of Ibuprofen tablets (1988).
23. Stability of reconstitute suspension of Cephalexin (1988).
24. In-vitro release characteristic for Nifedipine (1989).
25. Simultaneous determination of Metoprolol and HCTZ (1989).
26. Bioavailability and bioequivalence study of Metoprolol (1989).
27. Drug release profile from various sublingual tablets (1989).
28. Comparative evaluation of liquid antacid formulation (1989).
29. Effect of aging on DR profile of Prednisolone tablets (1989).
30. Evaluation of DR profile of marketed Piroxicam (1989).
31. Quantitative determination of Diclofenac in serum by HPLC (1990).
32. Effect of surfactant concentration in Rifampicin syrup (1990).
33. Comparative bioavailability of marketed Rifampicin (1990).
34. Determination of Rifampicin in serum by HPLC (1990).
35. Determination of Ceftriaxone in serum (1992).
36. Determination of Pefloxacin in serum by HPTLC (1993).
37. HPTLC method for monitoring degradation products of Rifampicin (1994).
38. Stability indicating HPLC determination of Cefaclor (1994).
39. HPLC determination of Cetirizine Dihydrochloride (1994).
Ready to Architect
Your Next Success?
Connect with our consultants to bring engineering precision and regulatory clarity to your pharmaceutical journey.